Article

Safety and immunogenicity of a single dose of a JN.1 variant COVID-19 vaccine in previously vaccinated adults: Primary analysis report of a phase 3 open-label trial

2025-08-24

Abstract excerpt

<h4>Background: </h4> We evaluated the immunogenicity and safety of a dose of NVX-CoV2705, a JN.1 subvariant SARS CoV-2 rS vaccine, in adults previously vaccinated with authorized/approved COVID-19 vaccines. <h4>Methods:</h4> Study 2019nCoV-315 is a Phase 3, open-label, single-arm study to evaluate the safety and immunogenicity of a single dose of NVX-CoV2705 in previously COVID-19 vaccinated adult participants ≥1...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 51c5c810-613a-55e3-b10e-430fd699175b
DOI: 10.1101/2025.08.20.25334074

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Safety and immunogenicity of a single dose of a JN.1 variant COVID-19 vaccine in previously vaccinated adults: Primary analysis report of a phase 3 open-label trialDOI 10.1101/2025.08.20.25334074Read

Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.1.7 VariantSemantic proximity Read

Immunogenicity and safety of NVX-CoV2373 as a homologous or heterologous booster: A phase 3 randomized clinical trial in adultsSemantic proximity Read

Safety and Immunogenicity of SII-NVX-CoV2373 (COVID-19 Vaccine) In Adults in a Phase 2/3, Observer-Blind, Randomised, Controlled StudySemantic proximity Read

Impact of the additional/booster dose of COVID-19 vaccine against severe disease during the epidemic phase characterized by the predominance of the Omicron variant in Italy, December 2021 - May 2022Semantic proximity Read

A systematic review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and diseaseSemantic proximity Read

Safety and Immunogenicity of Aerosolised Ad5-nCoV or Intramuscular Ad5-nCoV or Inactivated COVID-19 Vaccine Coronavac Given as the Second Booster Following Three Doses of CoronaVac: A Multicentre, Open-Label, Phase 4, Randomized TrialSemantic proximity Read

Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein VaccineSemantic proximity Read

Waning of SARS-CoV-2 vaccine-induced immunity: A systematic review and secondary data analysisSemantic proximity Read

An Open, Non-Randomised, 1/2 Phase Study on the Safety, Tolerability, and Immunogenicity of Single Dose 'Sputnik Light' Vaccine for Prevention of Coronavirus Infection in Healthy AdultsSemantic proximity Read

Facing the Omicron variant – How well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic reviewSemantic proximity Read

Immunogenicity and safety of LP.8.1 variant-containing mRNA COVID-19 vaccinesSemantic proximity Read

COVID-19 vaccinations: The unknowns, challenges, and hopes.Semantic proximity Read